Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779585 | 0.89 | AURKA (0.40) | AKT2MAPK14AURKAP2RX7NAMPT | |
| SCHEMBL2805915 | 0.88 | DHODH (0.41) | P2RX7NAMPTNPC1HDAC3RAB9A | |
| SCHEMBL2807472 | 0.85 | P2RX7 (0.39) | AKT2AURKAP2RX7HDAC3CNR2 | |
| Hydrochloric Acid SCHEMBL2805225 | 0.85 | P2RX7 (0.39) | AKT2AURKAP2RX7HDAC3CNR2 | |
| SCHEMBL2805231 | 0.82 | KMT2A (0.38) | AKT2NPC1RAB9AKMT2A | |
| SCHEMBL2805697 | 0.82 | RAB9A (0.41) | AKT2P2RX7NPC1RAB9AKMT2A | |
| SCHEMBL2808559 | 0.82 | F11 (0.39) | AKT2P2RX7NPC1RAB9AKMT2A | |
| SCHEMBL13128606 | 0.81 | BDKRB1 (0.42) | AURKAP2RX7NAMPTHDAC3CNR2 | |
| SCHEMBL2808168 | 0.80 | NPC1 (0.39) | AKT2MAPK14NPC1 | |
| Trifluoroacetic Acid SCHEMBL2809036 | 0.79 | RAB9A (0.38) | AKT2P2RX7NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | AKT2 3922/4885MAPK14 4129/4885AURKA 3494/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | AKT2 3922/4885MAPK14 4129/4885AURKA 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.